Lack of a significant effect of cannabinoids upon the uptake of 2-deoxy-D-glucose by Caco-2 cells

Pharmacology

Volumn 82, Issue 1, 2008, Pages 30-37

  Gonçalves, Pedro ^a   Araújo, João Ricardo ^a   Azevedo, Isabel ^a   Martel, Fátima ^a,b  

^a University of Porto   (Portugal)

^b Faculty of Medicine   (Portugal)

Author keywords

2 Deoxy D glucose; Caco 2 cells; Cannabinoids; Intestinal uptake

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; CYTOCHALASIN B; DEOXYGLUCOSE; DRONABINOL; PHLORIZIN; TRITIUM;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE ABSORPTION; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; INTESTINE EPITHELIUM; PRIORITY JOURNAL;

ARACHIDONIC ACIDS; CACO-2 CELLS; CANNABINOIDS; CYCLOHEXANOLS; DEOXYGLUCOSE; HUMANS; INDOLES; INTESTINAL ABSORPTION; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RECEPTORS, CANNABINOID; TETRAHYDROCANNABINOL;

EID: 46449111367     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000127408     Document Type: Article

References (61)

1. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL: Increasing prevalence of overweight among US adults. JAMA 1994;272:205-211.
2. Nisoli E, Carruba MO: Emerging aspects of pharmacotherapy for obesity and metabolic syndrome. Pharmacol Res 2004;50:453-469.
3. Haslam DW, James WPT: Obesity. Lancet 2005;366:1197-1209.
4. Mechoulam R:Looking back at Cannabis research. Curr Pharm Des 2000;6:1313-1322.
5. Kalant H: Medicinal use of cannabis: history and current status. Pain Res Manag 2001;6:80-91.
6. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ: Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004;47:345-358.
7. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG: International Union of Pharmacology. 27. Classification of cannabinoid receptors. Pharmacol Rev 2002;54:161-202.
8. Williams CM, Kirkham TC: Anandamide induces overeating: mediation by central cannabinoid receptors. Psychopharmacology (Berl) 1999;143:315-317.
9. Williams CM, Kirkham TC: Observational analysis of feeding induced by Delta9-THC and anandamide. Physiol Behav 2002;76:241-250.
10. Jamshidi N, Taylor DA: Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 2001;134:1151-1154.
11. Cota D, Marsicano G, Lutz B, Vicennati V, Stalla GK, Pasquali R, Pagotto U: Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 2003;27:289-301.
12. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G: Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410:822-825.
13. Harrold JA, Elliott JC, King PJ, Widdowson PS, Williams G: Downregulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? Brain Res 2002;952:232-238.
14. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, Pacher PI, Harvey-White J, Luft FC, Sharma AM, Jordan J: Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005;54:2838-2843.
15. Monteleone P, Matias I, Martiadis V, De Petrocellis L, Maj M, Di Marzo V: Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 2005;30:1216-1221.
16. Berry EM, Mechoulam R: Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 2002;95:185-190.
17. Mechoulam R, Hanus L: The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Res Manag 2001;6:67-73.
18. Pertwee RG: Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin Investig Drugs 2000;9:1553-1571.
19. Ravinet TC, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie P: Anti-obesity effect of SR141716, a CB 1 receptor antagonist, in diet-induced obese mice. Am J Physiol 2003;284:R345-R353.
20. 1 cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disorders. J Med Chem 2006;49:4008-4016.
21. 1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. CNS Drug Rev 2006;12:91-99.
22. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-1397.
23. 1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005;115:1298-1305.
24. Massa F, Storr M, Lutz B: The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J Mol Med 2005;83:944-954.
25. Sanger GJ: Endocannabinoids and the gastrointestinal tract: what are the key questions? Br J Pharmacol 2007;152:663-670.
26. Delie F, Rubas W: A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. Crit Rev Ther Drug Carrier Syst 1997;14:221-286.
27. Bradford MM:A rapid method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
28. Muzyka A, Tarkany O, Yelizanof V, Sergienko U, Boichuk A: Non-linear regression (curve fit). GraphPad Prism for Windows. San Diego, GraphPad Software Inc, 2005.
29. Kellett GL, Brot-Laroche E: Apical GLUT2: a major pathway of intestinal sugar absorption. Diabetes 2005;54:3056-3062.
30. Drozdowski LA, Thompson ABR: Intestinal sugar transport. World J Gastroenterol 2006;21:1657-1670.
31. Wright EM, Martín MG, Turk E: Intestinal absorption in health and disease - sugars. Best Pract Res Clin Gantroenterol 2003;17:943-956.
32. +/glucose co-transporter. Nature 1987;330:379-381.
33. +/glucose co-transporter gene SGLTI. J Biol Chem 1994;269:15204- 15209.
34. Thorens B, Sarkar HK, Kaback HR, Lodish HF: Cloning and functional expression in bacteria of a novel glucose transporter present in liver, intestine, kidney, and beta-pancreatic islet cells. Cell 1988;55:281-290.
35. Thorens B, Cheng ZQ, Brown D, Lodish HF: Liver glucose transporter: a basolateral protein in hepatocytes and intestine and kidney cells. Am J Physiol 1990;259:C279-C285.
36. Kellett GL: The facilitated component of intestinal glucose absorption. J Physiol 2001;531:585-595.
37. Affleck JA, Helliwell PA, Kellett GL: Immunocytochemical detection of GLUT2 at the rat intestinal brush-border membrane. J Histochem Cytochem 2003;51:1567-1574.
38. Au A, Gupta A, Schembri P, Cheeseman CI: Rapid insertion of GLUT2 into the rat jejunal brush-border membrane promoted by glucagon-like peptide 2. Biochem J 2002;367:247-254.
39. Gouyon F, Caillaud L, Carriere V, Klein C, Dalet V, Citadelle D, Kellett GL, Thorens B, Leturque A, Brot-Laroche E: Simple-sugar meals target GLUT2 at enterocyte apical membranes to improve sugar absorption: a study in GLUT2-null mice. J Physiol 2003;552:823-832.
40. Bissonnette P, GagnéH, Coady MJ, Benabdallah K, Lapointe JY, Berteloot A: Kinetic separation and characterization of three sugar transport modes in Caco-2 cells. Am J Physiol 1996 270:G833-G843.
41. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-1949.
42. Pertwee RG: Pharmacology of cannabinoid receptor ligands. Curr Med Chem 1999;6:635-664.
43. 1 receptors. Eur J Pharmacol 1996;307:331-338.
44. 35S]thio)-triphosphate binding assay in rat cerebellar membranes. J Pharmacol Exp Ther 1998;285:553-560.
45. Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH: Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 1998;285:285-292.
46. Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, Pertwee R, Makriyannis A: Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 1999;42:769-776.
47. 1 receptors. Life Sci 2005;76:1307-1324.
48. 35S] GTPγS binding in the mouse brain. Eur J Pharmacol 1997;321:R1-R3.
49. 1 receptor. Life Sci 1998;62:PL109-PL113.
50. Shivachar AC: Cannabinoids inhibit sodium-dependent, high-affinity excitatory amino acid transport in cultured rat cortical astrocytes. Biochemical Pharmacol 2007;73:2004-2011.
51. Kenney SP, Kekuda R, Prasad PD, Leibach FH, Devoe LD, Ganapathy V: Cannabinoid receptors and their role in the regulation of the serotonin transporter in human placenta. Am J Obstet Gynecol 1999;181:491-497.
52. 1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum. J Neurochem 2007;101:389-396.
53. Nieri P, Romiti N, Adinolfi B, Chicca A, Massarelli I, Chieli E: Modulation of P-glycoprotein activity by cannabinoid molecules in HK-2 renal cells. Br J Pharmacol 2006;148:682-687.
54. Carrier EJ, Auchampach JA, Hillard CJ: Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 2006;103:7895-7900.
55. Keating E, Gonçalves P, Campos I, Costa F, Azevedo I, Martel F: Effect of pathological conditions, pharmacotherapy and drugs of abuse upon folic acid placental uptake. FASEB J 2007;21:A602.16.
56. ob mice. Int J Obes 2005;29:183-187.
57. Gasperi V, Fezza F, Pasquariello N, Bari M, Oddi S, Finazzi AgròA, Maccarrone M: Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci 2007;64:219-229.
58. Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G, Bianchi K, Rizzuto R, Bernante P, Federspil G, Vettor R: The endogenous cannabinoid system stimulates glucose uptake in human fat cells via PI3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 2007;92:4810-4819.
59. 2 receptors in glucose homeostasis in rats. Eur J Pharmacol 2007;565:207-211.
60. 1 receptors induces glucose intolerance in rats. Eur J Pharmacol 2006;531:282-284.
61. 1 receptor antagonist, in diet-induced obese mice. Am J Physiol 2003;284:R345-R353.